Q-omics provides the consensus-scored BBS12 profile across patient tissues and cancer cell-line models. BBS12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BBS12 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, BBS12 RNA expression shows 19,605 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where BBS12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BBS12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BBS12 survival associations across molecular data types. BBS12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BBS12 RNA expression–survival associations across cancer types. High BBS12 expression shows unfavorable associations in LIHC, LGG and STAD, but favorable associations in KIRC, ACC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BBS12 RNA expression.
This table summarizes BBS12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for BBS12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BBS12 shows lower tumor expression in KICH, LUSC, THCA and BRCA and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher BBS12 RNA expression in normal versus tumor tissue (log2 FC = −1.788, t-test p < 0.001).
This table shows molecular features associated with BBS12 in patient tissues and cancer cell lines. In patient samples, BBS12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BBS12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
